{"product_id":"fulgentgenetics-marketing-mix","title":"Fulgent Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGet Inspired by a Complete Brand Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Fulgent’s product innovation, pricing architecture, distribution channels, and targeted promotions combine to drive market share and customer trust; the full 4Ps Marketing Mix Analysis delivers research-backed insights, ready-to-use slides, and practical recommendations to apply in strategy or coursework—get the complete, editable report to save time and act with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Oncology Profiling\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFulgent offers comprehensive genomic profiling for solid tumors and liquid biopsies using Next-Generation Sequencing (NGS) to identify actionable mutations and guide precision oncology; their oncology tests saw revenue grow ~38% YoY to $96 million in 2024. \u003c\/p\u003e\n\u003cp\u003eBy end-2025, integrating specialized pathology services increased test throughput by ~45% and strengthened Fulgent’s share in a global oncology diagnostics market projected at $29.5B in 2025. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare Disease and Pediatric Panels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFulgent maintains one of the largest genetic test menus—over 11,000 assays as of Dec 31, 2025—covering thousands of rare and pediatric conditions across specialties.\u003c\/p\u003e\n\u003cp\u003eTheir customizable NGS platform lets clinicians build patient-specific panels, reducing time-to-diagnosis; internal data show a 22% higher diagnostic yield in tailored panels versus static lists.\u003c\/p\u003e\n\u003cp\u003eGenetic counselors prefer Fulgent for complex pediatric cases; pediatric testing revenue was $78M in FY2025, up 14% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReproductive Health and Screening\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFulgent offers carrier screening and non-invasive prenatal testing (NIPT) with reported \u0026gt;99% analytic accuracy and median turnaround of 3–5 business days, supporting family planning and maternal health by enabling faster clinical decisions; revenue from reproductive services rose 18% in FY2024 to $72M, and management plans to expand capacity by late 2025 to meet a projected global NIPT market growth to $6.5B by 2025. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma and Clinical Trial Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpfulgent genetics leverages high-throughput sequencing to support pharma drug development and clinical trials offering biomarker discovery patient stratification that increased trial hit rates by in partnered programs drove\u003e30% gross margins in this segment as of FY2025.\n\u003cpthis high-margin services segment contributed roughly of revenue in growing at year-over-year and positioning fulgent for higher-margin recurring contracts with large pharma.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSequencing-led biomarker discovery\u003c\/li\u003e\n\u003cli\u003ePatient stratification to boost trial success ~15%\u003c\/li\u003e\n\u003cli\u003eSegment gross margins \u0026gt;30% in FY2025\u003c\/li\u003e\n\u003cli\u003e~18% of 2025 revenue, +22% YoY growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pfulgent\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Bioinformatics Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe proprietary bioinformatics platform is an integrated tech stack that automates analysis of massive genomic datasets using advanced algorithms, cutting per-sample analysis time by ~40% and reducing manual review errors by ~60% (internal 2025 QA). \u003c\/p\u003e\n\u003cp\u003eAs software-first infrastructure, it enables scaling to \u0026gt;1 million tests\/year without linear ops cost growth, lowering marginal cost per test by an estimated $8–$12 versus manual workflows. \u003c\/p\u003e\n\u003cp\u003eIt underpins diagnostic consistency, faster turnaround, and higher throughput for Fulgent’s testing services. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAutomates genomic analysis; ~40% faster per-sample\u003c\/li\u003e\n\u003cli\u003eReduces human error ~60% (2025 QA)\u003c\/li\u003e\n\u003cli\u003eSupports \u0026gt;1M tests\/year scale\u003c\/li\u003e\n\u003cli\u003eReduces marginal cost per test $8–$12\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFulgent: 11,000 Assays, Rapid Bioinformatics Cuts Costs as Oncology \u0026amp; Pharma Grow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFulgent’s product mix centers on NGS-based oncology and reproductive tests, a 11,000-assay menu (Dec 31, 2025), oncology revenue $96M (2024, +38% YoY), pediatric $78M (FY2025, +14%), reproductive $72M (FY2024, +18%), pharma services ~18% of 2025 revenue (+22% YoY) with \u0026gt;30% gross margins; bioinformatics cuts per-sample time ~40% and marginal cost $8–$12.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAssays\u003c\/td\u003e\n\u003ctd\u003e11,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology rev\u003c\/td\u003e\n\u003ctd\u003e$96M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePediatric rev\u003c\/td\u003e\n\u003ctd\u003e$78M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepro rev\u003c\/td\u003e\n\u003ctd\u003e$72M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma % rev\u003c\/td\u003e\n\u003ctd\u003e~18% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioinf time cut\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Fulgent’s Product, Price, Place, and Promotion strategies—grounded in actual practices and competitive context—ideal for managers, consultants, and marketers needing a ready-to-use, editable strategy brief for reports, workshops, or benchmarking.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Fulgent’s 4P marketing insights into a high-impact, at-a-glance summary that leaders can use for quick decisions and alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCentralized Laboratory Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFulgent runs high-capacity CLIA-certified, CAP-accredited labs in California and Texas that process specimens nationally; in 2025 they handled ~4.2 million tests and drove 68% of company lab revenue.\u003c\/p\u003e\n\u003cp\u003eBy 2025 these centralized hubs reached \u0026gt;10,000-sample daily throughput per site for oncology and rare-disease panels, cutting per-test processing cost ~22% versus 2022.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Market Presence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFulgent has built a meaningful international presence, especially in Asia via joint ventures and local partnerships covering China, Japan, and South Korea, contributing roughly 18% of 2024 revenue (about $74M of $410M total). This footprint lets them access high-growth genomics demand in APAC—projected regional CAGR ~12% through 2028—and eases navigation of local regs and cultural clinical workflows through on‑the‑ground teams and compliant labs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Physician Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClinicians access Fulgent services through a user-friendly online portal that handled over 1.2 million clinician logins in 2024, enabling fast test ordering and result retrieval within 24–48 hours for most panels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional and Hospital Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp significant portion of fulgent distribution flows from direct contracts with over large hospital systems and academic medical centers making institutional channels the primary recurring revenue source by end-2025 agreements drove roughly test volume about million in annualized\u003e\u003c\/p\u003e\n\u003cp\u003eThese partnerships embed Fulgent tests into standard-of-care workflows across major healthcare ecosystems, boosting repeat orders and brand loyalty; contract renewals hit a 92% rate in 2025, and institutional net promoter scores rose to 74.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003e\u0026gt;120 hospital systems; 40 academic centers\u003c\/li\u003e\n\u003cli\u003e48% of test volume (2025)\u003c\/li\u003e\n\u003cli\u003e$210M annualized revenue (2025)\u003c\/li\u003e\n\u003cli\u003e92% contract renewal rate (2025)\u003c\/li\u003e\n\u003cli\u003eNPS 74 (2025)\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Sample Collection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFulgent operates a national logistics network that moves samples from 4,500+ collection sites to central labs, supporting average transit under 24 hours and median lab turnaround of 36 hours in 2025.\u003c\/p\u003e\n\u003cp\u003eThey ship proprietary stabilized collection kits that maintain RNA\/DNA integrity for 72+ hours at ambient temps, lowering sample failure rates to under 0.8% versus industry ~2.5%.\u003c\/p\u003e\n\u003cp\u003eThis supply chain efficiency cut per-test logistics cost by ~12% in FY2024 and sustains Fulgent’s speed advantage over regional labs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4,500+ collection sites\u003c\/li\u003e\n\u003cli\u003e\u0026lt;24h average transit\u003c\/li\u003e\n\u003cli\u003e36h median turnaround\u003c\/li\u003e\n\u003cli\u003e72+h kit stability\u003c\/li\u003e\n\u003cli\u003e\u0026lt;0.8% failure rate\u003c\/li\u003e\n\u003cli\u003e~12% logistics cost reduction (FY2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFulgent: 4.2M tests (2025), $210M institutional revenue, 36h TAT, 4,500+ sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFulgent’s centralized CLIA\/CAP labs in CA\/TX processed ~4.2M tests in 2025 (68% lab revenue), with \u0026gt;10,000 daily throughput per site, cutting per-test cost ~22% vs 2022; institutional contracts (120+ hospital systems, 40 academic centers) drove 48% volume and ~$210M annualized revenue with 92% renewals and NPS 74; 4,500+ collection sites, \u0026lt;24h transit, 36h median TAT, 72+h kit stability, \u0026lt;0.8% failure.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTests processed\u003c\/td\u003e\n\u003ctd\u003e~4.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab revenue share\u003c\/td\u003e\n\u003ctd\u003e68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional revenue\u003c\/td\u003e\n\u003ctd\u003e$210M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional volume\u003c\/td\u003e\n\u003ctd\u003e48%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollection sites\u003c\/td\u003e\n\u003ctd\u003e4,500+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian TAT\u003c\/td\u003e\n\u003ctd\u003e36h\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eFulgent 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual document you’ll receive instantly after purchase—no surprises. This Fulgent 4P's Marketing Mix Analysis is fully complete, editable, and ready to use for strategy, presentations, or planning. You’re viewing the exact version included with your purchase, so buy with confidence. The file is final-quality and available for immediate download after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750299382137,"sku":"fulgentgenetics-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/fulgentgenetics-marketing-mix.png?v=1772224149","url":"https:\/\/matrixbcg.com\/products\/fulgentgenetics-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}